Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects

Shulman, 2014, Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach, J Multidiscip Healthc, 7, 489, 10.2147/JMDH.S49817

Hasnain, 2009, Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications, Prim Care Diabetes, 3, 5, 10.1016/j.pcd.2008.10.005

Laursen, 2013, Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries, PLoS One, 8, e67133, 10.1371/journal.pone.0067133

Stahl, 2013, “Meta-guidelines” for the management of patients with schizophrenia, CNS Spectr, 18, 150, 10.1017/S109285291300014X

Leucht, 2013, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet, 382, 951, 10.1016/S0140-6736(13)60733-3

Allison, 1999, Antipsychotic-induced weight gain: a comprehensive research synthesis, Am J Psychiatry, 156, 1686, 10.1176/ajp.156.11.1686

Taylor D, Paton C, Kapur S, editors. The Maudsley prescribing guidelines in psychiatry. 12th ed. West Sussex (UK): John Wiley & Sons;2015.

Musil, 2015, Weight gain and antipsychotics: a drug safety review, Expert Opin Drug Saf, 14, 73, 10.1517/14740338.2015.974549

Stroup, 2013, Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial, Schizophr Res, 146, 190, 10.1016/j.schres.2013.01.013

Bak, 2014, Almost all antipsychotics result in weight gain: a meta-analysis, PLoS One, 9, e94112, 10.1371/journal.pone.0094112

Pearsall, 2014, Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis, BMC Psychiatry, 14, 117, 10.1186/1471-244X-14-117

Baptista, 2002, Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives, Pharmacopsychiatry, 35, 205, 10.1055/s-2002-36391

Maayan, 2010, Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis, Neuropsychopharmacology, 35, 1520, 10.1038/npp.2010.21

Baptista, 2007, Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial, Schizophr Res, 93, 99, 10.1016/j.schres.2007.03.029

Atmaca, 2004, Nizatidine for the treatment of patients with quetiapine-induced weight gain, Hum Psychopharmacol Clin Exp, 19, 37, 10.1002/hup.477

Bustillo, 2003, Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients, Neuropsychopharmacology, 28, 527, 10.1038/sj.npp.1300089

Deberdt, 2005, Amantadine for weight gain associated with olanzapine treatment, Eur Neuropsychopharmacol, 15, 13, 10.1016/j.euroneuro.2004.03.005

Henderson, 2005, A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain, Am J Psychiatry, 162, 954, 10.1176/appi.ajp.162.5.954

Joffe, 2008, Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity, J Clin Psychiatry, 69, 706, 10.4088/JCP.v69n0503

Kim, 2006, 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia, Schizophr Res, 82, 115, 10.1016/j.schres.2005.10.001

Poyurovsky, 2007, Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study, Psychopharmacology, 192, 441, 10.1007/s00213-007-0731-1

Wu, 2008, Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial, JAMA, 299, 185, 10.1001/jama.2007.56-b

Álvarez-Jiménez, 2008, Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials, Br J Psychiatry, 193, 101, 10.1192/bjp.bp.107.042853

Faulkner, 2007, Interventions to reduce weight gain in schizophrenia, Cochrane Database Syst Rev, 10.1002/14651858.CD005148.pub2

Meyer, 2004, The effects of antipsychotic therapy on serum lipids: a comprehensive review, Schizophr Res, 70, 1, 10.1016/j.schres.2004.01.014

McEvoy, 2013, Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics, PLoS One, 8, e68717, 10.1371/journal.pone.0068717

Rummel-Kluge, 2010, Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis, Schizophr Res, 123, 225, 10.1016/j.schres.2010.07.012

Yan, 2013, Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia, Psychopharmacol (Berl), 229, 1, 10.1007/s00213-013-3193-7

Narula, 2010, Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial, Schizophr Res, 118, 218, 10.1016/j.schres.2010.02.001

Ojala, 2007, Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents, J Psychopharmacol, 22, 33, 10.1177/0269881107077815

Holt, 2004, Schizophrenia, the metabolic syndrome and diabetes, Diabet Med, 21, 515, 10.1111/j.1464-5491.2004.01199.x

Haupt, 2006, Differential metabolic effects of antipsychotic treatments, Eur Neuropsychopharmacol, 16, S149, 10.1016/j.euroneuro.2006.06.003

Gianfrancesco, 2002, Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database, J Clin Psychiatry, 63, 920, 10.4088/JCP.v63n1010

Koro, 2002, Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study, BMJ, 325, 243, 10.1136/bmj.325.7358.243

Teff, 2013, Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease, Diabetes, 62, 3232, 10.2337/db13-0430

Lindenmayer, 2003, Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics, Am J Psychiatry, 160, 290, 10.1176/appi.ajp.160.2.290

Newcomer, 2004, Metabolic risk during antipsychotic treatment, Clin Ther, 26, 1936, 10.1016/j.clinthera.2004.12.003

Rautaharju, 2009, AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram, J Am Coll Cardiol, 53, 982, 10.1016/j.jacc.2008.12.014

Bednar, 2001, The QT interval, Prog Cardiovasc Dis, 43, 1

Hasnain, 2014, QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review, CNS Drugs, 28, 887, 10.1007/s40263-014-0196-9

Shah, 2014, QTc prolongation with antipsychotics, J Psychiatr Pract, 20, 196, 10.1097/01.pra.0000450319.21859.6d

Vieweg, 2003, New generation antipsychotic drugs and QTc interval prolongation, Prim Care Companion J Clin Psychiatry, 5, 205, 10.4088/PCC.v05n0504

Khasawneh, 2014, Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia, Cardiol Res Pract, 2014, 273060, 10.1155/2014/273060

Young, 2015, “First do no harm”: a systematic review of the prevalence and management of antipsychotic adverse effects, J Psychopharmacol, 29, 353, 10.1177/0269881114562090

Cohn, 2006, Metabolic monitoring for patients treated with antipsychotic medications, Can J Psychiatry, 51, 492, 10.1177/070674370605100804

2004, Consensus development conference on antipsychotic drugs and obesity and diabetes, Diabetes Care, 27, 596, 10.2337/diacare.27.2.596